Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed. METHODS: A multicenter, randomized, double-blind controlled study was conducted to compare HD vaccine (which contains 60 microg of hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (which contains 15 microg of hemagglutinin per strain) in adults > or = 65 years of age. RESULTS: HD vaccine was administered to 2575 subjects, and SD vaccine was administered to 1262 subjects. There was a statistically significant increase in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vaccination among those who received HD vaccine, compared with those who received SD vaccine. Mean postvaccination titers for individuals who received HD vaccine were 116 for H1N1, 609 for H3N2, and 69 for B strain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2, and 52 for B strain. The HD vaccine met superiority criteria for both A strains, and the responses for B strain met non-inferiority criteria. Seroprotection rates were also higher for those who received HD vaccine than for those who received SD vaccine vaccine, for all strains. Local reactions were more frequent in individuals who received HD vaccine, but the reactions were mild to moderate. CONCLUSIONS: There was a statistically significant increase in the level of antibody response induced by HD influenza vaccine, compared with that induced by SD vaccine, without an attendant increase in the rate or severity of clinically relevant adverse reactions. These results suggest that the high-dose vaccine may provide improved protective benefits for older adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00391053 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [161]
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [69]
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodInfluenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 2×
“vaccine effectiveness are generally lower in older adults [1, 4-6].”
BackgroundResultHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002 · cited 2×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundGovaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly
Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070844 · Cited by 656 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 543 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MAN
POTTER, C. W., & OXFORD, J. S. (1979) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071545 · Cited by 452 · cited 1×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundVu, T., Farish, S., Jenkins, M., & Kelly, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 376 · cited 1×
“appears that efficacy is diminished in older age groups [18].”
BackgroundThe efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 265
Cited by
Items 101–200 of 388
Pneumonia immunization in older adults: review of vaccine effectiveness and strategies
El-Solh, A., Assaad, El-Masri, & Porhomayon, J. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s29675 · Cited by 57
Rosdahl, A., Herzog, C., Frösner, G., Norén, T., Rombo, L., & Askling, H. H. (2017) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2017.12.004 · Cited by 47
Dawood, F. S., Naleway, A. L., Flannery, B. L., Levine, M. Z., Murthy, K., Sambhara, S. R., Gangappa, S., Edwards, L., Ball, S. W., Grant, L. E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab566 · Cited by 53
“Similar criteria were used to determine superiority for immunogenicity outcomes in a phase III trial comparing high-dose to standard-dose influenza vaccine among persons ≥65 years [27].”
MethodVulnerability, distress, and immune response to vaccination in older adults
Segerstrom, S. C., Hardy, J. K., Evans, D. R., & Greenberg, R. N. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.10.009 · Cited by 57
Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
Hause, A. M., Zhang, B., Yue, X., Marquez, P. L., Myers, T. R., Parker, C., Gee, J. M., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.22241 · Cited by 47
Influenza in the Elderly – A Mini-Review
Pop-Vicas, A. E., & Gravenstein, S. (2010) · Gerontology · doi:10.1159/000319033 · Cited by 56
“The MF59-adjuvanted influenza vaccine has been licensed in Europe since 1997. In a study comparing standard-dose vaccines with a high-dose inactivated influenza vaccine the latter has been shown to be more immunogenic in people older than 65 [”
BackgroundVaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II
Crum‐Cianflone, N. F., & Sullivan, E. L. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0165-y · Cited by 50
Ross, K. A., Senapati, S., Alley, J., Darling, R. J., Goodman, J., Jefferson, M. A., Uz, M., Guo, B., Yoon, K. J., Verhoeven, D. E., et al. (2019) · Biomaterials Science · doi:10.1039/c8bm01443d · Cited by 48
Comber, L., Murchú, É. Ó., Jordan, K., Hawkshaw, S., Marshall, L., O’Neill, M., Teljeur, C., Ryan, M., Carnahan, A., Martín, J. J. P., et al. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2330 · Cited by 50
“During the 6 month follow‐up period in the study conducted by Falsey et al.43 one diagnosis of Crohn's disease and one of Myasthenia Gravis were noted.”
BackgroundMethodInfluentialImmunization in End‐Stage Renal Disease: Opportunity to Improve Outcomes
Soni, R., Horowitz, B., & Unruh, M. L. (2013) · Seminars in Dialysis · doi:10.1111/sdi.12101 · Cited by 45
“A booster dose of vaccine improved response rates in the elderly (97), and in hemodialysis patients (98) as did a high-dose influenza vaccination (99).”
BackgroundLevin, Y., Kochba, E., Shukarev, G., Rusch, S., Herrera-Taracena, G., & van Damme, P. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.09.008 · Cited by 45
Influenza (Including Avian Influenza and Swine Influenza)
Treanor, J. J. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00167-3 · Cited by 51
Self-citationForrest, B. D., Steele, A. D., Hiemstra, L. A., Rappaport, R., Ambrose, C. S., & Gruber, W. C. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.03.029 · Cited by 43
Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1 H -benzimidazol-2-amines
Beesu, M., Malladi, S. S., Fox, L. M., Jones, C. D., Dixit, A., & David, S. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500701q · Cited by 44
Merani, S., Kuchel, G. A., Kleppinger, A., & McElhaney, J. E. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.09.015 · Cited by 45
“The HD vaccine was designed to overcome these changes and has been shown to significantly increase antibody responses in older adults when compared to SD vaccines (Couch et al., 2007; Falsey et al., 2009; DiazGranados et al., 2013; DiazGranados et al., 2014).”
InfluentialVaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I
Crum‐Cianflone, N. F., & Sullivan, E. L. (2017) · Infectious Diseases and Therapy · doi:10.1007/s40121-017-0166-x · Cited by 46
Couch, R. B., Bayas, J. M., Caso, C., Mbawuike, I. N., López, C. N., Claeys, C., Idrissi, M. E., Hervé, C., Laupèze, B., Oostvogels, L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-425 · Cited by 42
“Strategies to improve vaccine immunogenicity in older adults include vaccination with a higher dose of antigen [7,8] and the use of adjuvants [6].”
BackgroundSamson, S., Leventhal, P. S., Salamand, C., Meng, Y., Seet, B. T., Landolfi, V. A., Greenberg, D., & Hollingsworth, R. C. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1575734 · Cited by 47
“45 (106/73) Falsey 2009 [15] 4 2006–2007 Day 28 2,543 1,252 1.”
BackgroundMethodInfluentialThomas-Crusells, J., McElhaney, J. E., & Aguado, M. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.025 · Cited by 43
Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity
Caldera, F., Mercer, M., Samson, S., Pitt, J. M., & Hayney, M. S. (2021) · Vaccine · doi:10.1016/j.vaccine.2020.11.037 · Cited by 47
Long, C. B., Ramos, I., Rastogi, D., Manwani, D. G., Janow, G. L., Rio, M. D., Mayers, M. M., Herold, B. C., Fernández-Sesma, A., & Madan, R. P. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.06.045 · Cited by 41
“The Fluzone® High-Dose TIV formulation contains 60 mcg of HA antigen for each of the three viral strains included in the vaccine, is more immunogenic compared with standard formulation in individuals > 65 years, and could prove more immunogenic in high risk pediatric populations [24–26].”
BackgroundIntradermal influenza vaccine and new devices: a promising chance for vaccine improvement
Ansaldi, F., Durando, P., & Icardi, G. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557658 · Cited by 42
“Studies investigating the use of 60 μg antigen dose vaccine in older adults demonstrated higher GMT, seroprotection and seroconversion rates compared with that observed in subjects immunized with standard-dose vaccine (15 μg of each strain), but the incidence of adverse events, generally mild or moderate, was higher i…”
ResultLaguio-Vila, M. R., Thompson, M. G., Reynolds, S. B., Spencer, S., Gaglani, M., Naleway, A. L., Ball, S. W., Bozeman, S., Baker, S. F., Martínez‐Sobrido, L., et al. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu115 · Cited by 40
Self-citationAntibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults
Vanderven, H. A., Jegaskanda, S., Wines, B. D., Hogarth, P. M., Carmuglia, S., Rockman, S. P., Chung, A. W., & Kent, S. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix554 · Cited by 45
“High dose and adjuvanted influenza vaccines improve efficacy in older adults [15–18], but increase reactogenicity [16].”
BackgroundLópez‐Medrano, F., Cordero, E., Gavaldà, J., Cruzado, J. M., Marcos, M. Á., Pérez‐Romero, P., Sabé, N., Gómez‐Bravo, M. Á., Delgado, J. F., Cabral, E., et al. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.01.013 · Cited by 42
Busse, W. W., Peters, S. P., Fenton, M. J., Mitchell, H., Bleecker, E. R., Castro, M., Wenzel, S. E., ERZURUM, S. C., Fitzpatrick, A. M., Teague, W. G., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.014 · Cited by 39
“Recent studies using high dose (60mcg) TIV have demonstrated higher immunogenicity than standard dose vaccine for individuals >65y[22,23].”
BackgroundSuggested use of vaccines in diabetes
Kesavadev, J., Misra, A., Das, A., Saboo, B., Basu, D., Thomas, N., Joshi, S., Unnikrishnan, A., Shankar, A., Krishnan, G., et al. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.102982 · Cited by 41
“[24] In clinical studies, Fluzone High-Dose demonstrated an enhanced immune response compared with Fluzone in individuals aged 65 years and older.[29]”
BackgroundValli, E., Harriett, A. J., Nowakowska, M. K., Baudier, R. L., Provosty, W. B., McSween, Z., Lawson, L. B., Nakanishi, Y., & Norton, E. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-51356-w · Cited by 39
Pépin, S., Nicolas, J., Szymański, H., Leroux‐Roels, I., Schaum, T., Bonten, M. J. M., Icardi, G., Shrestha, A., Tabar, C., & The QHD00011 study team (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1983387 · Cited by 39
“11,13,16,21 The efficacy of high-dose versus standard-dose vaccine has also been evaluated in a large Phase IIIb–IV, multicenter, randomized, double-blind trial, which showed that IIV3-HD induced significantly higher HAI responses compared with IIV3-SD, and this corresponded to improved protection…”
BackgroundCioppa, G. D., Nicolay, U., LINDERT, K. A., Leroux-Roels, G. G., Clément, F., Castellino, F., Galli, G., Groth, N., & Giudice, G. D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.18445 · Cited by 37
Influenza vaccination in solid-organ transplant recipients
Cordero, E., & Manuel, O. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283592622 · Cited by 37
McManus, M. P., Frangoul, H., McCullers, J. A., Wang, L., O’Shea, A., & Halasa, N. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24863 · Cited by 36
“The majority of these earlier studies; however, reported that lower antibody titers were achieved in individuals with cancer, including children with ALL, when compared to healthy controls [23].”
BackgroundInfluentialFry, A. M., Kim, I. K., Reed, C., Thompson, M. G., Chaves, S. S., Finelli, L., & Bresee, J. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu328 · Cited by 35
“antibody levels have been demonstrated in older adults for both adjuvanted and high-dose inactivated influenza vaccines compared with standard-dose inactivated vaccines [8–10].”
BackgroundShapiro, J. R., Li, H., Morgan, R., Chen, Y., Kuo, H., Ning, X., Shea, P., Wu, C., Merport, K., Saldanha, R., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00412-6 · Cited by 38
Doyle, J., Beacham, L. A., Martin, E. T., Talbot, H. K., Monto, A. S., Gaglani, M., Middleton, D. B., Silveira, F. P., Zimmerman, R. K., Alyanak, E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa160 · Cited by 39
Sahly, H. M. E., Davis, C. E. L. B., Kotloff, K. L., Meier, J. L., Winokur, P. L., Wald, A., Johnston, C., George, S. L., Brady, R. C., Lehmann, C. E., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir837 · Cited by 33
“Increasing the antigen content of seasonal influenza vaccines is a licensed method to improve the immunogenicity of seasonal influenza vaccines in older persons in the United States [22, 23].”
Influenza vaccine strategies for solid organ transplant recipients
Hirzel, C., & Kumar, D. (2018) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000461 · Cited by 33
Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?
Chambers, C., Skowronski, D. M., Rose, C., Serres, G. D., Winter, A., Dickinson, J. A., Jassem, A. N., Gubbay, J. B., Fonseca, K., Drews, S. J., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy211 · Cited by 39
Double Dose vs. Standard Dose Influenza Vaccination in Patients with Heart Failure: A Pilot Study
Ermen, A. V., Hermanson, M. P., Moran, J. M., Sweitzer, N. K., Johnson, M. R., & Vardeny, O. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs207 · Cited by 35
Cioppa, G. D., Nicolay, U., LINDERT, K. A., Leroux-Roels, G. G., Clément, F., Castellino, F., Galli, C., Groth, N., Levin, Y., & Giudice, G. D. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28618 · Cited by 31
Vaccine strategies to enhance immune responses in the aged
Lefebvre, J. S., & Haynes, L. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.05.014 · Cited by 37
Jamshed, S., Walsh, E. E., Dimitroff, L. J., Santelli, J. S., & Falsey, A. R. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.12.037 · Cited by 31
Self-citationVaccines for Acinetobacter baumannii: Thinking “out of the box”
Pérez, F., & Bonomo, R. A. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.031 · Cited by 33
Seasonal influenza immunisation: Strategies for older adults
Schaffner, W., Buynder, P. G. V., McNeil, S., & Osterhaus, A. D. M. E. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13249 · Cited by 31
Comparative Reactogenicity of Enhanced Influenza Vaccines in Older Adults
Cowling, B. J., Thompson, M. G., Ng, T. W. Y., Fang, V. J., Perera, R. A. P. M., Leung, N., Chen, Y., So, H. C., Ip, D., & Iuliano, A. D. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa255 · Cited by 30
Dhar, R., Ghoshal, A. G., Guleria, R., Sharma, S., Kulkarni, T., Swarnakar, R., Samaria, J., Chaudhary, S., Gaur, S., Christopher, D., et al. (2020) · Lung India · doi:10.4103/lungindia.lungindia_270_20 · Cited by 32
“Further, there was no proportionate increase in the incidence and severity of clinically relevant adverse reactions with HD versus SD.[54-56] For elderly patients (>65 years), in a single-blind comparative trial, the HD of influenza vaccine was associated with a significantly lower incidence of respiratory-related hos…”
InfluentialAlvarez, F. P., Chevalier, P., Borms, M., Bricout, H., Marques, C., Soininen, A., Sainio, T., Petit, C., & de Courville, C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2194193 · Cited by 28
“The HD influenza vaccine has shown greater immunogenicity, efficacy, and effectiveness than standard-dose vaccines in adults 65years old and older 18 – 20 while having an acceptable safety profile.”
BackgroundMaternal vaccination for the prevention of influenza: current status and hopes for the future
Phadke, V. K., & Omer, S. B. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1175304 · Cited by 29
Biggerstaff, M., Reed, C., Swerdlow, D. L., Gambhir, M., Graitcer, S. B., Finelli, L., Borse, R. H., Rasmussen, S. A., Meltzer, M. I., & Bridges, C. B. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu1175 · Cited by 28
“For the second scenario, we assumed a high VE due to the use of higher concentrations of hemagglutinin antigen [18] or the addition of an adjuvant to the vaccine [19].”
Hendriks, J., Hutubessy, R. C. W., Grohmann, G. S., Torelli, G., Friede, M., & Kiény, M.-P. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.099 · Cited by 33
Schmader, K. E., Liu, C., Harrington, T. A., Rountree, W., Auerbach, H., Walter, E. B., Barnett, E. D., Schlaudecker, E. P., Todd, C. A., Poniewierski, M. S., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.31266 · Cited by 28
Lu, Y., Chillarige, Y., Izurieta, H. S., Wei, Y., Xu, W., Lu, M., Sung, H.-M., Lindaas, A., Wernecke, M., MaCurdy, T. E., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz360 · Cited by 33
Trombetta, C. M., Marchi, S., & Montomoli, E. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2085565 · Cited by 29
Lingblom, C., Kowli, S., Swaminathan, N., Maecker, H. T., & Lambert, S. L. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1528-1 · Cited by 31
“Those meant for elderly subjects may benefit from inclusion of an adjuvant [13–15] or an increased antigen dose [16, 17].”
BackgroundInfluenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis
Yang, X., Zhao, H., Li, Z., Zhu, A., Ren, M., Geng, M., Li, Y., Qin, Y., Feng, L., Peng, Z., et al. (2021) · Vaccines · doi:10.3390/vaccines9020079 · Cited by 30
Hajj vaccinations—facts, challenges, and hope
Ghany, M. A. E., Sharaf, H., & Hill-Cawthorne, G. A. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.05.024 · Cited by 27
Kim, J. H., Talbot, H. K., Mishina, M., Zhu, Y., Chen, J., Cao, W., Reber, A. J., Griffin, M. R., Shay, D. K., Spencer, S. M., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.018 · Cited by 27
“While the superior immunogenicity of HD vaccines has been characterized by serological parameters [6, 15, 22] the increasingly recognized clinical relevance of CMI in this population warrants a comprehensive understanding of HD-mediated immunogenicity.”
BackgroundMethodMombelli, M., Neofytos, D., Huynh‐Do, U., Sánchez‐Céspedes, J., Stampf, S., Golshayan, D., Dahdal, S., Stirnimann, G., Schnyder, A., Garzoni, C., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad477 · Cited by 35
“Our results are in accordance with previous studies demonstrating improved humoral responses to the high-dose and MF59-adjuvanted vaccines in the elderly [11, 21, 22].”
ResultProtecting Pediatric Oncology Patients From Influenza
Kersun, L. S., Reilly, A. F., Coffin, S. E., & Sullivan, K. E. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0401 · Cited by 27
Chaves, S. S., Naeger, S., Lounaci, K., Zuo, Y., Loiacono, M. M., Pilard, Q., Nealon, J., Genin, M., & Mahé, C. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad322 · Cited by 26
“The high-dose (HD) influenza vaccine, licensed for persons aged ≥ 65 years, contains 4 times more antigen than standard-dose (SD) vaccines, inducing significantly higher antibody responses that correlate with better protection against laboratory-confirmed influenza [3–7].”
BackgroundHuman influenza vaccines and assessment of immunogenicity
Zakay‐Rones, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.144 · Cited by 26
Inactivated Influenza Vaccines
Bresee, J., Fry, A. M., Sambhara, S. R., & Cox, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00031-6 · Cited by 32
Influenza Vaccines: Unmet Needs and Recent Developments
Noh, J. Y., & Kim, W. J. (2013) · Infection and Chemotherapy · doi:10.3947/ic.2013.45.4.375 · Cited by 36
Vaccination in Patients With Inflammatory Bowel Disease
Caldera, F., Hayney, M. S., & Farraye, F. A. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000713 · Cited by 25
Johansen, N. D., Modin, D., Nealon, J., Samson, S., Salamand, C., Larsen, C. S., Claggett, B. L., Solomon, S. D., Landray, M., Gislason, G., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-01044-w · Cited by 25
“Previous studies have shown that antibody response and protection elicited by the standard formulation influenza vaccine are reduced for individuals aged 65 years or older as compared to younger adults [7, 8].”
BackgroundGravenstein, S., Dahal, R., Gozalo, P. L., Davidson, H. E., Han, L., Taljaard, M., & Mor, V. (2016) · Clinical Trials · doi:10.1177/1740774515625976 · Cited by 25
Chiem, K., Rangel‐Moreno, J., Nogales, A., & Martínez‐Sobrido, L. (2019) · Journal of Visualized Experiments · doi:10.3791/59890 · Cited by 24
Plant, E. P., Fredell, L. J., Hatcher, B. A., Li, X., Chiang, M., Košíková, M., Xie, H., Zoueva, O., Cost, A. A., Ye, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05579-4 · Cited by 24
Redondo, E., Drago, G., López-Belmonte, J. L., Guillén, J. M., Bricout, H., Alvarez, F. P., Callejo, D., & de Miguel, Á. G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.048 · Cited by 27
Flynn, P. M., Nachman, S., Muresan, P., Fenton, T., Spector, S. A., Cunningham, C. K., Pass, R. F., Yogev, R., Burchett, S. K., Heckman, B., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis360 · Cited by 23
“levels of serum antibodies that recognize antigenically distinct drift variants [23] and can overcome suboptimal responses in immunologically impaired vaccinees, such as elderly patients [22, 24, 25].”
BackgroundChen, W. H., Winokur, P. L., Edwards, K. M., Jackson, L. A., Wald, A., Walter, E. B., Noah, D. L., Wolff, M., & Kotloff, K. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.044 · Cited by 23
“[18–21] In part because of insufficient data demonstrating greater protection from influenza infection (these studies are ongoing), national advisory committees have not expressed a preference for the higher dose versus the standard dose of TIV containing 15 hemagglutinin per strain.”
BackgroundBalancing the Efficacy and Safety of Vaccines in the Elderly
Amanna, I. J. (2012) · Open Longevity Science · doi:10.2174/1876326x01206010064 · Cited by 24
“In one double-blinded placebo controlled study carried out in persons ≥65 years of age, the high -dose formulation gave both higher seroconversion rates, as well as increasing antibody titers up to 80% when compared to the standard dose [45].”
BackgroundThe Prevention of Infections in Older Adults: Vaccination
Coll, P. P., Costello, V. W., Kuchel, G. A., Bartley, J. M., & McElhaney, J. E. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16205 · Cited by 24
Adult Immunizations: Update on Recommendations
Pham, H., Geraci, S. A., & Burton, M. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.07.032 · Cited by 22
The Burden of Vaccine-preventable Diseases in Patients With Inflammatory Bowel Disease
Kröner, P. T., Picco, M. F., Cangemi, J. R., Hayney, M. S., Farraye, F. A., & Caldera, F. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001635 · Cited by 24
Serum 25-Hydroxyvitamin D Level and Influenza Vaccine Immunogenicity in Children and Adolescents
Science, M. E., Maguire, J. L., Russell, M. L., Smieja, M., Walter, S. D., & Loeb, M. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083553 · Cited by 23
“Although strategies such as an increase in vaccine dose, intradermal injection, and use of adjuvants have been shown to increase immunogenicity [4–6], little is known about the effect of vitamins on influenza vaccine antibody response.”
BackgroundDiazGranados, C. A., Saway, W., Gouaux, J., Baron, M., Baker, J. P., Denis, M., Jordanov, E., Landolfi, V. A., & Yau, E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.131 · Cited by 22
Pillsbury, A., Fathima, P., Quinn, H., Cashman, P. M., Blyth, C. C., Leeb, A., & Macartney, K. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.4079 · Cited by 22
A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests
Sasaki, E., Kuramitsu, M., Momose, H., Kobiyama, K., Aoshi, T., Yamada, H., Ishii, K. J., Mizukami, T., & Hamaguchi, I. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.12.036 · Cited by 21
Arsenović-Ranin, N., Petrović, R., Zivkovic, I. P., Bufan, B., Stoiljković, V., & Leposavić, G. (2019) · Biogerontology · doi:10.1007/s10522-019-09811-8 · Cited by 22
Carter, C., Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J. M., Enama, M. E., Sarwar, U. N., Larkin, B. D., Bailer, R. T., Koup, R. A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222178 · Cited by 21
The effect of sex on responses to influenza vaccines
Denly, L. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1830685 · Cited by 23
“…studies observed antibody responses to be greater in females than males following immunization.25–29 For example, post-hoc analyses carried out by Falsey et al. (2009) in a randomized controlled trial of the TIV found females to have greater HAI geometric mean titers.27 This difference was most…”
BackgroundMethodInfluentialInter-individual variation in health and disease associated with pulmonary infectious agents
Verhein, K. C., Vellers, H. L., & Kleeberger, S. R. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9733-z · Cited by 26
“A few studies have reported females have greater antibody responses to influenza vaccination than males (Engler et al. 2008; Falsey et al. 2009; GiefingKröll et al. 2015).”
BackgroundSanchez, L., Matsuoka, O., Inoue, S., Inoue, T., Meng, Y., Nakama, T., Kato, K., Pandey, A., & Chang, L.-J. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1677437 · Cited by 21
“Although this study was not designed or powered to make statistical comparisons between IIV4-HD and IIV4-SD, the results are similar to those from studies comparing IIV3-HD and IIV3-SD in this population.(14,23,24) Because influenza vaccines are typically administered by SC injection in Japan and IM injection in the U…”
ResultInfluentialHigh-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults
Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager‐Pedersen, M., Claggett, B. L., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.3460 · Cited by 22
Influenza infection in human host: challenges in making a better influenza vaccine
Virk, R. K., Gunalan, V., & Tambyah, P. A. (2016) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1155450 · Cited by 20
“The trivalent inactivated vaccines (TIV) produced annually are currently targeted against the circulating H3N2, pdmH1N1/09, and an influenza B lineage strains as determined by the WHO and come in three formulations: whole virus, detergent-split, and subunit vaccines.”
BackgroundInfluentialCD46-Mediated Transduction of a Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy
Camacho, Z. T., Turner, M. A., Barry, M. A., & Weaver, E. A. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.215 · Cited by 22
“Although recent studies have shown that high-dose influenza vaccine formulations have been shown to improve the vaccine efficacy in the elderly and immunocompromised, there is still a need to improve the current vaccine technology (Falsey et al., 2009; McKittrick et al., 2013).”
Strategies to maximize influenza vaccine impact in older adults
Whitaker, J. A., von Itzstein, M. S., & Poland, G. A. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.040 · Cited by 21
Poland, G. A., Fleming, D., Treanor, J. J., Maraskovsky, E., Luke, T. C., Ball, E. M. A., & Poland, C. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.033 · Cited by 19
Self-citationLu, Y., Chillarige, Y., Izurieta, H. S., Wei, Y., Xu, W., Lu, M., Sung, H.-M., Lindaas, A., Wernecke, M., MaCurdy, T. E., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz463 · Cited by 20
Girard, M. P., Tam, J. S., Pervikov, Y., & Katz, J. M. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.06.047 · Cited by 18
“As reviewed by Robert Atmar (Baylor College of Medicine, Houston, TX, USA), a high-dose TIV containing 60 μg HA per influenza virus strain was successfully tested in adults 65 years of age or older and shown to elicit a significantly increased HAI titer, higher rates of seroconversion and achievement of HAI titers >40…”
MethodArakane, R., Annaka, R., Takahama, A., Ishida, K., Yoshiike, M., Nakayama, T., & Takeshita, F. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.10.088 · Cited by 19
Lai, J.-J., Lin, C. S., Ho, C., Chen, P., & Lee, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050590 · Cited by 19
“A pivotal phase III trial in older adults demonstrated that HD-IIV3 (60 μg) had similar safer and greater immunogenicity than SD-IIV3 (15 μg HA/strain) [30].”
Backgroundvan Aalst, R., Russo, E. M., Neupane, N., Mahmud, S. M., Mor, V., Wilschut, J., Chit, A., Postma, M. J., & Young‐Xu, Y. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.066 · Cited by 18
Seasonal influenza vaccination and technologies
Nafziger, A. N., & Pratt, D. S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.299 · Cited by 21
Kaka, A. S., FILICE, G. A., Myllenbeck, S., & Nichol, K. L. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx001 · Cited by 18
“However, the similarity of our findings to the prior report in the literature supports the validity of our findings [18].”
BackgroundResultInfluentialClark, T. W., Tregoning, J. S., Fisher, H. R., Poletti, T., Amin, F., & Nguyen‐Van‐Tam, J. S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00025-24 · Cited by 24
“The higher doses of HA induce increased post-vaccination HA-specific antibody titers and provide increased protection from influenza, which makes them particularly appropriate for use in older people (194–196).”
Puig‐Barberà, J., Natividad-Sancho, A., Calabuig-Pérez, J., Rodrigo, J. A. L., Pastor-Villalba, E., Martínez-Úbeda, S., & Díez‐Domingo, J. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.095 · Cited by 19
A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly
Mullikin, M., Tan, L., Jansen, J. P., Ranst, M. A. V., Farkas, N., & Petri, E. (2015) · Infectious Diseases and Therapy · doi:10.1007/s40121-015-0076-8 · Cited by 18
“Attempts to increase immunogenicity have been made with alternatives such as high-dose TIV (60 lg of hemagglutinin (HA)/strain) [18] and an intradermal vaccine [19].”
Butler, A. M., Layton, J. B., Dharnidharka, V. R., Sahrmann, J. M., Seamans, M. J., Weber, D. J., & McGrath, L. J. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.018 · Cited by 17
“HDV is also more reactogenic, causing more frequent side effects, although most of these adverse events are minor (eg, injection-site reactions, systemic adverse events, and gastrointestinal events).(12,19,44-48) Safety data for the HDV”
Background
Metadata
- Authors
- Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J.
- Affiliations
- University of Rochester Medicine (US)
- St. Louis VA Medical Center (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-15
- Volume
- 200
- Issue
- 2
- Pages
- 172-180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2164949714
- Cited by
- 388
- References
- 22
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 12 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 25 · 2019: 33 · 2018: 25 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 32 · 2013: 34 · 2012: 24
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- high-dose influenza vaccine, standard-dose influenza vaccine, immunogenicity, older adults, seroconversion, hemagglutination inhibition titers, trivalent inactivated influenza vaccine, vaccine dose comparison, local adverse reactions, seroprotection rate
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.